These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 2736110

  • 1. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
    Unger C, Damenz W, Fleer EA, Kim DJ, Breiser A, Hilgard P, Engel J, Nagel G, Eibl H.
    Acta Oncol; 1989; 28(2):213-7. PubMed ID: 2736110
    [Abstract] [Full Text] [Related]

  • 2. Hexadecylphosphocholine: a new and selective antitumor drug.
    Eibl H, Unger C.
    Cancer Treat Rev; 1990 Sep; 17(2-3):233-42. PubMed ID: 2272038
    [Abstract] [Full Text] [Related]

  • 3. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
    Unger C, Peukert M, Sindermann H, Hilgard P, Nagel G, Eibl H.
    Cancer Treat Rev; 1990 Sep; 17(2-3):243-6. PubMed ID: 2272039
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo antitumoral activity of alkylphosphonates.
    Ries UJ, Fleer EA, Breiser A, Unger C, Stekar J, Fenneberg K, Eibl H.
    Eur J Cancer; 1992 Sep; 29A(1):96-101. PubMed ID: 1445752
    [Abstract] [Full Text] [Related]

  • 5. Tumor heterogeneity and chemosensitivity to cyclophosphamide, vinblastine and hexadecylphosphocholine.
    Angres G, Scherf HR, Schmähl D.
    Cancer Treat Rev; 1990 Sep; 17(2-3):339-45. PubMed ID: 2272049
    [No Abstract] [Full Text] [Related]

  • 6. Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug.
    Unger C, Eibl H.
    Lipids; 1991 Dec; 26(12):1412-7. PubMed ID: 1819743
    [Abstract] [Full Text] [Related]

  • 7. Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
    Unger C, Eibl H, Breiser A, von Heyden HW, Engel J, Hilgard P, Sindermann H, Peukert M, Nagel GA.
    Onkologie; 1988 Dec; 11(6):295-6. PubMed ID: 3071766
    [No Abstract] [Full Text] [Related]

  • 8. Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).
    Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl H, Unger C, Berger MR.
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1457-61. PubMed ID: 3141197
    [Abstract] [Full Text] [Related]

  • 9. Alkyl phosphocholines: toxicity and anticancer properties.
    Muschiol C, Berger MR, Schuler B, Scherf HR, Garzon FT, Zeller WJ, Unger C, Eibl HJ, Schmähl D.
    Lipids; 1987 Nov; 22(11):930-4. PubMed ID: 3444388
    [Abstract] [Full Text] [Related]

  • 10. Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo.
    Sobottka SB, Berger MR, Eibl H.
    Int J Cancer; 1993 Feb 01; 53(3):418-25. PubMed ID: 8428795
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats.
    Scherf HR, Schuler B, Berger MR, Schmähl D.
    Lipids; 1987 Nov 01; 22(11):927-9. PubMed ID: 3444387
    [Abstract] [Full Text] [Related]

  • 12. Induction of resistance in the human leukemia cell line HL60 towards hexadecylphosphocholine and other ether phospholipid analogues.
    Berkovic D, Haase D, Hiddemann W, Fleer EA.
    J Exp Ther Oncol; 1996 Nov 01; 1(6):368-75. PubMed ID: 9414427
    [Abstract] [Full Text] [Related]

  • 13. Miltefosine in recurrent cutaneous breast cancer.
    Clive S, Leonard RC.
    Lancet; 1997 Mar 01; 349(9052):621-2. PubMed ID: 9057742
    [No Abstract] [Full Text] [Related]

  • 14. Distribution and metabolism of hexadecylphosphocholine in mice.
    Breiser A, Kim DJ, Fleer EA, Damenz W, Drube A, Berger M, Nagel GA, Eibl H, Unger C.
    Lipids; 1987 Nov 01; 22(11):925-6. PubMed ID: 3444386
    [Abstract] [Full Text] [Related]

  • 15. Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites.
    Bishop FE, Dive C, Freeman S, Gescher A.
    Cancer Chemother Pharmacol; 1992 Nov 01; 31(2):85-92. PubMed ID: 1451237
    [Abstract] [Full Text] [Related]

  • 16. D-21266, a new heterocyclic alkylphospholipid with antitumour activity.
    Hilgard P, Klenner T, Stekar J, Nössner G, Kutscher B, Engel J.
    Eur J Cancer; 1997 Mar 01; 33(3):442-6. PubMed ID: 9155530
    [Abstract] [Full Text] [Related]

  • 17. In vitro investigations on the antineoplastic effect of hexadecylphosphocholine.
    Yanapirut P, Berger MR, Reinhardt M, Schmähl D.
    Arzneimittelforschung; 1991 Jun 01; 41(6):652-5. PubMed ID: 1930356
    [Abstract] [Full Text] [Related]

  • 18. Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133.
    Stekar J, Hilgard P, Voegeli R, Maurer HR, Engel J, Kutscher B, Nössner G, Schumacher W.
    Cancer Chemother Pharmacol; 1993 Jun 01; 32(6):437-44. PubMed ID: 8258191
    [Abstract] [Full Text] [Related]

  • 19. Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine.
    Kaufmann-Kolle P, Berger MR, Unger C, Eibl H.
    Adv Exp Med Biol; 1996 Jun 01; 416():165-8. PubMed ID: 9131143
    [No Abstract] [Full Text] [Related]

  • 20. Antitumor activity of alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas.
    Berger MR, Yanapirut P, Reinhardt M, Klenner T, Scherf HR, Schmeiser HH, Eibl H.
    Prog Exp Tumor Res; 1992 Jun 01; 34():98-115. PubMed ID: 1438807
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.